M. C. Muller

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Lida Kalmanti, Michael Lauseker, M. C. Muller et al. · Leukemia · 2015 · 274 citations

Medicine, Pharmacology, Pharmacotherapy +5

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

Kirsten Merx, M. C. Muller, Sebastian Kreil et al. · Leukemia · 2002 · 172 citations

Life Sciences, Hematology, Molecular Biology +15

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Benjamin Hanfstein, Valeria Shlyakhto, Michael Lauseker et al. · Leukemia · 2014 · 138 citations

Medicine, Hematology, Molecular Biology +9

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Andreas Hochhaus, Gianantonio Rosti, Nicholas C.P. Cross et al. · Leukemia · 2015 · 107 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +8

Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization

M. C. Muller, Kirsten Merx, A Weiβer et al. · Leukemia · 2002 · 63 citations

Medicine, Hematology, Oncology +16